35 / 53
Duration of PFS (months)
PFS (%)
PFS (%)
PFS by prior RT in patients with
CNS Metastases at Baseline*
*Investigator assessed
Gadgeel, et al. ESMO 2017
12.7
(95% CI: 7.2–
14.6)
NR
(95% CI: 11.0–NR)
7.2
(95% CI:
3.9–8.6)
14.0
(5.6–NR)
Patients who had received
prior RT
100
80
60
40
20
0
9
15
21
27
6
12
18
24
30
3
Day 1
Patients who had
not received prior RT
Duration of PFS (months)
9
15
21
27
6
12
18
24
30
3
Day 1
100
80
60
40
20
0
HR=
0.34
p=0.0078
HR=
0.
44
p=0.0041
Alectinib (n=25)
Crizotinib (n=21)
Alectinib (n=39)
Crizotinib (n=37)